ENSC
Income statement / Annual
Last year (2024), Ensysce Biosciences, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Ensysce Biosciences, Inc.'s net income was -$7.99 T.
See Ensysce Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$2.23 M |
$2.52 M |
$3.53 M |
$3.93 M |
$1.76 M |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$7.59 M
|
$19.84 M
|
$151.00
|
$1.37 M
|
$3.33 M
|
$1.56 M
|
$0.00
|
| Gross Profit |
$0.00
|
-$5.36 M
|
-$17.31 M
|
$3.53 M
|
$2.56 M
|
-$1.56 M
|
-$1.56 M
|
$0.00
|
| Gross Profit Ratio |
0
|
-2.4
|
-6.86
|
1
|
0.65
|
-0.89
|
0
|
0
|
| Research and Development Expenses |
$7.22 T
|
$7.59 M
|
$19.84 M
|
$4.69 M
|
$4.39 M
|
$3.40 M
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$4.72 T
|
$5.36 M
|
$6.91 M
|
$18.71 M
|
$1.15 M
|
$6.93 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$3.60 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.72 T
|
$5.36 M
|
$6.91 M
|
$18.71 M
|
$1.15 M
|
$3.33 M
|
$1.56 M
|
$146,695.00
|
| Other Expenses |
$0.00
|
-$7.59 M
|
-$2.52 M
|
-$3.53 M
|
-$3.93 M
|
$0.00
|
$600,000.00
|
$0.00
|
| Operating Expenses |
$11.94 T
|
$5.36 M
|
$24.22 M
|
$19.87 M
|
$1.61 M
|
$3.33 M
|
$959,245.00
|
$146,695.00
|
| Cost And Expenses |
$0.00
|
$12.95 M
|
$24.22 M
|
$19.87 M
|
$1.61 M
|
$3.33 M
|
$959,240.00
|
$146,695.00
|
| Interest Income |
$0.00
|
$0.00
|
$1.25 M
|
$3.22 M
|
$719,646.00
|
$4.25 M
|
$3.63 M
|
$0.00
|
| Interest Expense |
-$1.29 T
|
$353,945.00
|
$109,525.00
|
$1.30 M
|
$995,496.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
-$3.00
|
$151.00
|
$151.00
|
$201.00
|
$201.00
|
$161,141.00
|
$0.00
|
| EBITDA |
-$6.73 T |
-$10.72 M |
-$24.22 M |
-$19.87 M |
-$1.61 M |
$921,154.00 |
$2.68 M |
-$27,555.00 |
| EBITDA Ratio |
0
|
-4.81
|
-9.6
|
-5.63
|
-0.41
|
-1.89
|
0
|
0
|
| Operating Income Ratio |
0
|
-4.81
|
-9.6
|
-5.63
|
-0.41
|
-1.89
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.26 T
|
$91,912.00
|
$14,410.00
|
-$9.28 M
|
$1.45 M
|
$4.25 M
|
$3.64 M
|
$119,142.00
|
| Income Before Tax |
-$7.99 T
|
-$10.63 M
|
-$24.21 M
|
-$29.15 M
|
-$160,875.00
|
$921,154.00
|
$2.68 M
|
-$27,558.00
|
| Income Before Tax Ratio |
0
|
-4.76
|
-9.59
|
-8.25
|
-0.04
|
0.52
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$753,876.00
|
-$151.00
|
$777,851.00
|
-$555,200.00
|
$553,916.00
|
$3,635.00
|
| Net Income |
-$7.99 T
|
-$10.61 M
|
-$24.96 M
|
-$29.15 M
|
-$938,726.00
|
$1.48 M
|
-$1.34 M
|
-$31,193.00
|
| Net Income Ratio |
0
|
-4.76
|
-9.89
|
-8.25
|
-0.24
|
0.84
|
0
|
0
|
| EPS |
-11448.17 |
-4.69 |
-138.73 |
-346.9 |
-14.29 |
15.02 |
-12.91 |
-0.3 |
| EPS Diluted |
-11448.17 |
-4.69 |
-138.73 |
-346.9 |
-13.65 |
15.02 |
-12.91 |
-0.3 |
| Weighted Average Shares Out |
$697.69 M
|
$2.26 M
|
$179,932.00
|
$84,018.00
|
$65,703.00
|
$98,262.00
|
$104,015.00
|
$105,000.00
|
| Weighted Average Shares Out Diluted |
$697.69 M
|
$2.26 M
|
$179,932.00
|
$84,018.00
|
$68,780.00
|
$98,262.00
|
$104,015.00
|
$105,000.00
|
| Link |
|
|
|
|
|
|
|
|
